A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients
Hematologic Malignancy, Hematopoietic/Lymphoid Cancer, Blood Cancer
About this trial
This is an interventional other trial for Hematologic Malignancy focused on measuring Hematopoietic Stem Cell Transplant, Positive Psychology, Hematologic malignancy, Positive Psychological Intervention
Eligibility Criteria
Inclusion Criteria:
- Adult patients with hematologic malignancies hospitalized for allogeneic HSCT at the DFCI inpatient units who are medically stable and appropriate for study approach
- Ability to speak, read and write English
- Access to a telephone
Exclusion Criteria:
- Current major depressive episode, bipolar disorder, psychosis or active substance use disorder diagnosed via the Mini International Neuropsychiatric Interview (MINI)
- Cognitive deficits impeding a study participant's ability to provide informed consent or participate adequately in the study assessed via the Brief Interview for Mental Status (BIMS)
- Medical conditions precluding interviews
Sites / Locations
- Dana Farber Cancer Institute
Arms of the Study
Arm 1
Experimental
Positive Psychology
Participants will receive check-in/psychosocial support phone calls at weeks four, eight and twelve following enrollment. At approximately 100-days post-HSCT, participants will begin an 8-week positive-psychology program involving weekly calls with an interventionist, in this case the principal investigator, and exercises (i.e. writing a letter of gratitude, identifying personal strengths, planning meaningful and enjoyable activities). Participants will complete self-assessment questionnaires to measure positive affect, health behaviors, and overall function before and after completing the Positive Psychology Intervention.